December 25, 2014 4:52 PM ET

Biotechnology

Company Overview of Enumeral Biomedical Holdings, Inc.

Company Overview

Enumeral Biomedical Holdings, Inc. discovers and develops novel antibody immunotherapies that help immune system to attack diseased cells. It focuses on developing a pipeline of product candidates (immunomodulators) for the treatment of cancer and inflammatory diseases. The company was formerly known as Enumeral Biomedical Corp. and changed its name to Enumeral Biomedical Holdings, Inc. in August 2014. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

One Kendall Square

Building 400

Fourth Floor

Cambridge, MA 02139

United States

Founded in 2009

Phone:

617-674-1865

Fax:

617-945-9148

Key Executives for Enumeral Biomedical Holdings, Inc.

Co-Founder
Age: 47
Total Annual Compensation: $250.0K
Co-Founder and Executive Chairman
Age: 61
Total Annual Compensation: $200.0K
Vice President of Business Development and Secretary
Age: 37
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2013.

Enumeral Biomedical Holdings, Inc. Key Developments

Enumeral Biomedical Holdings, Inc. and Merck Sharp & Dohme Corp. Form Collaboration for Predicting Clinical Drug Response with Human-Driven Immune Profiling Platform

Enumeral Biomedical Holdings, Inc. announced that it has signed an oncology-focused collaborative study agreement with Merck Sharp & Dohme Corp. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies.

Enumeral Biomedical Holdings, Inc. Appoints Paul Sekhri to its Board of Directors

On December 16, 2014, Paul Sekhri was appointed to the board of directors of Enumeral Biomedical Holdings, Inc. Mr. Sekhri will serve as a Class III director of Enumeral for a term expiring in 2017 or until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Sekhri was appointed to the Board in accordance with the provisions of that certain Voting Agreement, dated as of July 31, 2014, by and among Enumeral and certain stockholders named therein, and is designated the ‘Montrose Director’ by Montrose Capital Limited and EDI Financial, Inc. Mr. Sekhri has not been named to any committees of the Board at the time of his appointment.

Enumeral Biomedical Holdings, Inc. Appoints Robert L. Van Nostrand to its Board of Directors

Enumeral Biomedical Holdings, Inc. announced that it has appointed Robert L. Van Nostrand to its board of directors. Most recently, Mr. Van Nostrand held senior executive positions with AGI Dermatics and Aureon BioSciences. Mr. Van Nostrand currently serves on the boards of several other publicly traded biotechnology companies, including Metabolix, where he is chairman, Achillion Pharmaceuticals and Intra-Cellular Therapies. Mr. Van Nostrand also serves as the chairman of the audit committee for each of these companies. In addition, Mr. Van Nostrand serves on the board of directors of the Biomedical Research Alliance of New York.

Similar Private Companies By Industry

Company Name Region
Core Quantum Technologies, Inc. United States
Interpace Diagnostics, LLC United States
Mosaic Biosciences, Inc. United States
STC Biologics, Inc. United States
Aurora Biotechnologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 4, 2014
--
Merger/Acquisition
August 4, 2014
Enumeral Biomedical Holdings, Inc., Prior to Reverse Merger with Enumeral Biomedical Corp.
Private Placement
April 25, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enumeral Biomedical Holdings, Inc., please visit www.enumeral.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.